Xolair vs Nucala
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Xolair | US Nucala | |
|---|---|---|
| Generic name | omalizumab | mepolizumab |
| Drug class | Anti-IgE Monoclonal Antibody | IL-5 Antagonist (Biologic) |
| Treats | Allergic asthma, chronic hives, food allergy | Severe eosinophilic asthma, COPD, nasal polyps |
| Category | Respiratory | Respiratory |
| Manufacturer | Genentech/Novartis | GSK |
| Year approved | 2003 | 2015 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $95M | $75M |
| Common side effects | Anaphylaxis (severe allergic reaction), Injection site reactions, Joint pain, Headache | Headache, Injection site reactions, Back pain, Fatigue |
Frequently asked questions
Is Xolair or Nucala better?
Neither is universally "better." Xolair (omalizumab) and Nucala (mepolizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xolair and Nucala?
Xolair is a Anti-IgE Monoclonal Antibody made by Genentech/Novartis, while Nucala is a IL-5 Antagonist (Biologic) made by GSK. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xolair has the larger estimated TV advertising budget of the two.